Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

QuidelOrtho Earnings Call: Key Takeaways

QuidelOrtho is undergoing a major restructuring to offset severe China headwinds and high leverage, shifting to a business-unit model while narrowing revenue guidance downward.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal revenue $619M, down 12%; China down 45%; Labs ex-China up 4%.
Mgmt ConfidenceCautious on China and respiratory; confident in $80M structural cost savings.
Demand VisibilityChina destocking accelerated; respiratory testing remains lower than historical norms.
Margin TrendsAdjusted gross margin 47.8%, down 90 bps; EBITDA margin 24%.
Op. LeverageRestructuring to deliver $80M savings; OpEx declined 3% to $210M.
Pricing PowerChina pricing pressured by nationwide IVD guidelines and lower reimbursement rates.
Vol vs PriceGrowth driven by ex-China volume; China hit by price and volume.
Segment GrowthLabs and Immunohematology grew low-to-mid single digits excluding China.
Capex & DebtNet debt $2.8B; leverage 4.5x; CapEx reduced to $19M from $49M.
RegulatoryChina nationwide IVD pricing guidelines impacting provincial implementation and reimbursement.
CommentaryEvolving from regional to business-unit model: Core Diagnostics and Point of Care.
New LaunchesExpanding Vitros 450 launch; building manufacturing for Sofia and Lexa platforms.

Growth

Total revenue declined 12% constant currency; Labs grew 4% and Immunohematology 3% excluding China.

Outlook

Targeting $80 million annual savings by 2027; China revenue expected to drop to 4-5% in 2027.

Risks

China revenue fell 45%; management pivoted on specific asset sale rumors while prioritizing deleveraging.

Source

The company's earnings call, NASDAQ: QDEL, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

QuidelOrtho Corp: key numbers

Share price
$10.21Close, Nov 16
Market cap
$701M
Shares outstanding
68.61MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from QuidelOrtho Corp

All →
6:00 AM ET 10-Q
Financial Results ▶ Call

QuidelOrtho Q3 2026 Results: Net Loss of $53.8M, Loss Narrows

QuidelOrtho reported a net loss of $53.8 million for the third quarter of 2026, a significant improvement from the $733.0 million loss in the prior year which was driven by a large goodwill impairment. Total revenues decreased to $618.9 million from $699.9 million year-over-year, while the company's accumulated deficit grew to $1,234.5 million.

Key figure
Net loss $53.8M
4:10 PM ET 8-K
Financial Results

QuidelOrtho Financial Results

QuidelOrtho reported Q3 2026 revenue of $619 million, a 12% decrease year-over-year primarily due to lower sales in China and a softer respiratory season. The company also announced a major cost transformation and restructuring program expected to deliver over $80 million in annual savings by 2027, involving a shift to two focused business units: Core Diagnostics and Point of Care Diagnostics.

Term
Q3 2026

“The underlying performance of our Labs and Immunohematology businesses remained solid in the third quarter, supported by the strength and durability of our customer relationships and our large global installed base. While China and a softer respiratory season continue to pressure our results, we are taking decisive action to strengthen the Company through a new cost transformation and enterprise restructuring program.”

Brian J. Blaser, President and Chief Executive Officer
4:41 PM ET 8-K
Loan & Debt

QuidelOrtho $3.4B Debt Financing with Bank of America, N.A.

QuidelOrtho Corporation entered into an amendment to its existing credit agreement to reset financial covenant levels through September 30, 2029, providing a 'Covenant Relief Period' with adjusted leverage and interest coverage ratios. The underlying $3.4 billion financing package includes a $1.15 billion Term Loan A, a $100 million delayed draw facility, a $1.45 billion Term Loan B, and a $700 million revolving credit facility.

Value
$3.4B
Counterparty
Bank of America, N.A.
Term
through Sep 2029

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.